Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod for high-grade anal intraepithelial neoplasia in gay men
ISRCTN96401551Phase 3Completed
- Sponsor
- United States Department of Health and Human Services
- Start
- Oct 2002
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of imiquimod in anal intraepithelial neoplasia (AIN) and human papillomavirus infection, sponsored by United States Department of Health and Human Services. Primary endpoint: Complete clearance of AIN 2/3 lesions. Started Oct 2002; status: completed.
02
Drugs
imiquimod
03
Conditions
anal intraepithelial neoplasia (AIN)human papillomavirus infection
Beyond the preview
Go deeper on ISRCTN96401551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN96401551.